Overexpression of aldo-keto-reductase in azole-resistant clinical isolates of Candida glabrata determined by cDNA-AFLP
- Shirin Farahyar1,
- Farideh Zaini†1Email author,
- Parivash Kordbacheh1,
- Sassan Rezaie1,
- Mahin Safara1,
- Reza Raoofian3 and
- Mansour Heidari†2
© Farahyar et al.; licensee BioMed Central Ltd. 2013
Received: 26 August 2012
Accepted: 29 December 2012
Published: 2 January 2013
Candida glabrata causes significant medical problems in immunocompromised patients. Many strains of this yeast are intrinsically resistant to azole antifungal agents, and treatment is problematic, leading to high morbidity and mortality rates in immunosuppressed individuals. The primary goal of this study was to investigate the genes involved in the drug resistance of clinical isolates of C. glabrata.
The clinical isolates of C. glabrata were collected in an epidemiological survey of candidal infection in immunocompromised patients and consisted of four fluconazole and itraconazole resistant isolates, two fluconazole and itraconazole sensitive isolates, and C. glabrata CBS 138 as reference strain. Antifungal susceptibility patterns of the organisms were determined beforehand by the Clinical and Laboratory Standards Institute (CLSI). The potential gene(s) implicated in antifungal resistance were investigated using complementary DNA- Amplified Fragment Length Polymorphism (cDNA-AFLP). Semi-quantitative RT-PCR was carried out to evaluate the expression of gene(s) in resistant isolates as compared to sensitive and reference strains.
Results and conclusions
The aldo-keto-reductase superfamily (AKR gene) was upregulated in the resistant clinical isolates as assessed by cDNA-AFLP. Semi-quantitative RT-PCR revealed AKR mRNA expression approximately twice that seen in the sensitive isolates. Overexpression of the AKR gene was associated with increased fluconazole and itraconazole resistance in C. glabrata. The data suggest that upregulation of the AKR gene might give a new insight into the mechanism of azole resistance.
KeywordsAzole Aldo-keto-reductase cDNA-AFLP Candida glabrata Semi-quantitative RT-PCR
The incidence of fungal infections has increased over the past two decades. Opportunistic fungal infections occur in immunocompromised hosts , particularly among patients infected with human immunodeficiency virus (HIV), individuals receiving immunosuppressive therapy for organ or stem cell transplantation, and cancer patients . Candida glabrata has emerged as a common fungal pathogen in many countries and is often reported as the second most prevalent species after C. albicans. Candida glabrata appears to be innately resistant to fluconazole [4, 5] and is less sensitive to it than C. albicans, C. parapsilosis, or C. tropicalis. Studies have shown that mechanisms of azole resistance in C. glabrata are often associated with the upregulation of the genes CgCDR1 (C. glabrata Candida drug resistance), CgCDR2 (formerly PDH1) [6, 7], and CgSNQ2 (C. glabrata sensitivity to 4-nitroquinoline N-oxide) which encode proteins belonging to ATP binding cassette (ABC) transporters . CgSNQ2 was controlled by CgPDR1 (C. glabrata pleiotropic drug resistance 1) . A further azole resistance mechanism in C. glabrata has been shown to be the mutation or overexpression of the ERG11 gene (CgERG11) that encodes cytochrome P-450 lanostrol 14-α demethylase, the azole target enzyme, and increases CYP51 (the ERG11 orthologue) activity, enhancing azole resistance . ERG11 is a well-characterized gene implicated in the fluconazole resistance of Candida krusei and Candida albicans[6, 11, 12]. The molecular mechanisms in the resistant strains of C. glabrata are not completely understood. In this study, antifungal resistance mechanisms were investigated using cDNA-AFLP, a genome-wide expression analysis method that does not require prior sequence knowledge of the genes . This technology is an ideal alternative to microarrays .
Materials and methods
Number of isolates, site of isolation and azole susceptibility of Candida glabrata clinical isolates used in this study
Site of isolation
Culture conditions and drug susceptibility testing
The isolates and reference strain were cultured on a yeast extract peptone-glucose (YEPD) agar plate containing 5 g/l yeast extract (Baltimore Biological Laboratory, USA), 10 g/l peptone (Merck, Germany), 20 g/l glucose (Merck, Germany), 0.5 g/l chloramphenicol; and 20 g/l agar (Biolife, Italy) incubated at 37°C for 72 h. A single colony of each isolates and reference strain was selected and subcultured in YEPD broth for 24 h at 37°C. Resistant isolate No. 51 was cultured in YEPD broth with fluconazole (128 μg/ml) for 48 h at 37°C. Susceptibility to fluconazole and itraconazole drugs was determined by microdilution according to the criteria for Clinical and Laboratory Standards Institute (CLSI) M27–A2 (formerly NCCLS) [15, 16].
Total RNA was extracted from the exponential phase using the RNeasy Protect Mini Kit (Qiagen, Germany). For mechanical disruption, the yeast cells were sonicated with acid-washed glass beads (0.45–0.52 mm diameter). The released RNA was treated through an RNase-free DNase step (Qiagen, Germany) and quantity and quality of RNA was measured with the Nanodrop 1000 spectrophotometer (Thermo Scientific, USA).
Primers used in this study
Gene location (5′-3′)
Product size (bp)
Adaptors used in cDNA-AFLP method
Isolation, cloning, and sequencing of cDNA-AFLP fragments
Selected bands were isolated from the PAGE and re-amplified using appropriate sensitive adaptors. The TDFs were cloned using a TA-cloning kit (Invitrogen, USA) and the recombinant plasmids were screened using M13 forward (−20) (5′-GTAAAACGACGGCCAG-3′) and M13 reverse (5′-CAGGAAACAGCTATGAC-3′) primers with the following PCR protocol: 30 cycles of 94°C for 1 min, 55°C for 1 min; 72 C for 1 min; and 72°C for 7 min. PCR products were analyzed by agarose gel electrophoresis . The recombinant plasmids containing unknown DNA were sequenced by M13 forward (−20) and M13 reverse primers. Some TDFs were verified with direct sequencing (Macrogene, Korea). Sequence data were analyzed in non-redundant nucleic and protein databases BLAST (http://www.ncbi.nim.nih.gov/BLAST/).
Semi-quantitative RT-PCR was carried out to evaluate the mRNA overexpression level of TDFs, which were identified by cDNA-AFLP  using specifically designed primers (Table 2). An equal amount (6 μg) of total RNA from each of the clinical isolates and the CBS 138 reference strain was used for first strand cDNA synthesis, and the expression pattern in cDNA-AFLP was determined with the primers on RNA of clinical isolates. The URA3 gene was used as internal control and negative controls were prepared with sterile water as template. The gel image was captured digitally with a Sony XC-ST50CE camera (Sony, Japan). The band intensity was analyzed and quantified with gel analysis software UVI (Roche, Germany).
Susceptibility to fluconazole and itraconazole was determined by the broth microdilution method described in the CLSI (document M27-A2). The minimum inhibitory concentration (MIC) of fluconazole and itraconazole obtained against clinical isolates of C. glabrata showed four strains resistant to fluconazole (MIC 64 μg/ml) and itraconazole (MIC 2–4 μg/ml), while two strains were susceptible to fluconazole (MIC 0.25–0.50 μg/ml) and itraconazole (MIC 0.25–0.50 μg/ml) (Table 1).
The cDNA-AFLP products of clinical isolates and reference strain
Sequences identified by cDNA-AFLP
Candida glabrata, second only to C. albicans as an infectious pathogen in candidiasis, contributes to an average of 11% of candidal infections, varying from 7% to 20% depending on geographic location . In the survey providing data for the present study of immunocompromised patients, C. glabrata accounted for about 15% of candidal infections. Twenty-five percent of the isolates were resistant to fluconazole (Zaini et al., unpublished data). Although several genes may be implicated in azole resistance, the molecular pathways involved are not completely understood.
We report, for the first time using cDNA-AFLP, AKR transcripts upregulated in resistant clinical isolates. The AKR gene is not the first suggested to be involved in azole resistance. Upregulation of CgCDR1 and CgCDR2 genes associated with increased expression of the ABC transporter has been well documented [19, 20]. The PDR1 gene is important in acquired azole resistance , and so-called gain-of-function mutations of the CgPDR1 gene have been shown to play an essential role in azole resistance by C. glabrata[22–25]. These mutations indicate that many genes are differentially regulated in azole resistant isolates as compared to the wild type. Multiple genes (from 27–235) show increased expression, and aldo-keto-reductase (CAGL0C04543g: XM_445372.1) is upregulated (1.5 to 2-fold) . The results of the present study also demonstrated that AKR mRNA expression in azole resistance reaches levels of about twice that found in sensitive strains. The molecular mechanisms of azole resistance in C. albicans are connected with overexpression of ATP-binding cassette (ABC) transporters or major facilitator superfamily, and upregulation of these genes can also be brought about by exposure to benomyl and fluphenazine. In the presence of benomyl, some genes belonging to the aldo-keto reductase family, such as IFD genes, IPF5987, and GRP2, can be activated with the oxido-reductase function .
The aldo-keto-reductase superfamily (AKR) comprises several proteins with similar kinetic and structural properties and has been found in a wide range of phyla, including both prokaryotes and eukaryotes . AKRs catalyze the reduction of aldehydes and ketones to their corresponding alcohol products by reducing nicotinamide adenine dinucleotide phosphate (NADPH) cofactor . Several drugs and pharmaceuticals are reactive carbonyls and aldehydes or are converted to carbonyls during in vivo metabolism. An important role of AKRs is in preventing carbonyl toxicity . The physiological roles of this superfamily have been studied in the yeast Saccharomyces cerevisiae, a simple eukaryote containing various AKR genes that encode proteins similar in structure and function to mammalian AKRs, including those of humans. The physiological activity of yeast AKRs is largely unclear. Prior studies have identified six open reading frames (YHR104W, YOR120W, YDR368W, YBR149W, YJR096W, YDL124W) in the S. cerevisiae genome that encode proteins with activity overlapping human aldose reductase . YHR104W and YDR368W are stress response proteins . The product of YOR120W is a galactose-inducible crystalline-like yeast protein, and YBR149W encodes a dehydrogenase that plays a role in the direction of arabinose oxidation rather than reduction . Numerous studies have demonstrated that aldo-keto-reductases are active in stress conditions. Another important role of the yeast AKR genes is to protect against heat shock stress . In addition, AKRs potentially play roles in oxidative defense and transcriptional regulation . AKR function has also been reported in drug metabolism and detoxification of pharmaceuticals, drugs, and xenobiotics in humans , and it seems that the physiological roles of the AKR gene in yeast are similar to those in humans. Our results suggest upregulation of AKR gene is involved in the molecular mechanism of drug resistance in C. glabrata.
Aldo-keto-reductases are important in intermediary metabolism, detoxification, and stress conditions. The AKR gene was highly expressed in azole resistant C. glabrata, and may be associated with the biological networks of drug resistance factors of C. glabrata. To the best of our knowledge, this study is the first to report the implication of AKR in azole resistance among C. glabrata clinical isolates, using the cDNA-AFLP technique. Further investigations are needed to clarify the role of this gene.
ATP binding cassette
Complementary DNA-amplified fragment length polymorphism
- CgCDR1 Candida glabrata Candida :
drug resistance 1
- CgCDR2 Candida glabrata Candida :
drug resistance 2
- CgPDR1 Candida glabrata :
pleiotropic drug resistance
- CgSNQ2 Candida glabrata :
sensitivity to 4-nitroquinoline N-oxide
Major facilitator superfamily
The authors thank Dr. Hossein Mirhendi, Professor in Department of Medical Mycology & Parasitology, School of Public Health, Tehran University of Medical Sciences, and Professor Koichi Makimura of Teikyo University Institute of Medical Mycology for kindly providing the reference strain (CBS 138). This research was supported by Tehran University of Medical Sciences and Health Services grants 11438. This study represents a part of the PhD dissertation by Shirin Farahyar.
- Pfaller M, Diekema D: Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007, 20: 133-163. 10.1128/CMR.00029-06.PubMed CentralView ArticlePubMed
- Richardson M, Lass-Flörl C: Changing epidemiology of systemic fungal infections. Clin Microbiol Infect. 2008, 14: 5-24.View ArticlePubMed
- Ruhnke M: Epidemiology of Candida albicans infections and role of non-Candida-albicans yeasts. Curr Drug Targets. 2006, 7: 495-504. 10.2174/138945006776359421.View ArticlePubMed
- Fidel PL, Vazquez JA, Sobel JD: Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev. 1999, 12: 80-96.PubMed CentralPubMed
- Perea S, Patterson TF: Antifungal resistance in pathogenic fungi. Clin Infect Dis. 2002, 35: 1073-1080. 10.1086/344058.View ArticlePubMed
- Akins RA: An update on antifungal targets and mechanisms of resistance in Candida albicans. Med Mycol. 2005, 43: 285-318. 10.1080/13693780500138971.View ArticlePubMed
- Sanguinetti M, Posteraro B, Fiori B, Ranno S, Torelli R, Fadda G: Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother. 2005, 49: 668-679. 10.1128/AAC.49.2.668-679.2005.PubMed CentralView ArticlePubMed
- Sanglard D, Ischer F, Bille J: Role of ATP-binding-cassette transporter genes in high-frequency acquisition of resistance to azole antifungals in Candida glabrata. Antimicrob Agents Chemother. 2001, 45: 1174-1183. 10.1128/AAC.45.4.1174-1183.2001.PubMed CentralView ArticlePubMed
- Torelli R, Posteraro B, Ferrari S, La Sorda M, Fadda G, Sanglard D, Sanguinetti M: The ATP binding cassette transporter–encoding gene CgSNQ2 is contributing to the CgPDR1 dependent azole resistance of Candida glabrata. Mol Microbiol. 2008, 68: 186-201. 10.1111/j.1365-2958.2008.06143.x.View ArticlePubMed
- Marichal P, Vanden Bossche H, Odds FC, Nobels G, Warnock DW, Timmerman V, Van Broeckhoven C, Fay S, Mose-Larsen P: Molecular biological characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother. 1997, 41: 2229-2237.PubMed CentralPubMed
- Lamping E, Ranchod A, Nakamura K, Tyndall JDA, Niimi K, Holmes AR, Niimi M, Cannon RD: Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei. Antimicrob Agents Chemother. 2009, 53: 354-369. 10.1128/AAC.01095-08.PubMed CentralView ArticlePubMed
- Tavakoli M, Zaini F, Kordbacheh M, Safara M, Raoofian R, Heidari M: Upregulation of the ERG11 gene in Candida krusei by azoles. DARU J Pharm Sci. 2010, 18: 276-280.
- Jayaraman A, Puranik S, Rai NK, Vidapu S, Sahu PP, Lata C, Prasad M: cDNA-AFLP analysis reveals differential gene expression in response to salt stress in foxtail millet (Setaria italica L.). Mol Biotechnol. 2008, 40: 241-251. 10.1007/s12033-008-9081-4.View ArticlePubMed
- Reijans M, Lascaris R, Groeneger AO, Wittenberg A, Wesselink E, van Oeveren J, Wit E, Boorsma A, Voetdijk B, van der Spek H: Quantitative comparison of cDNA-AFLP, microarrays, and GeneChip expression data in Saccharomyces cerevisiae. Genomics. 2003, 82: 606-618. 10.1016/S0888-7543(03)00179-4.View ArticlePubMed
- National Committe for Clinical Laboratory Standards: NCCLS document M27-A2 National Committee for Clinical Laboratory Standards 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts. 2002, Wayne, Pa: NCCLS
- Falahati M, Shabani M, Rodaki MMA, Jahaniani F, Bagheri KP, Ebrahimi SA: Interaction between ketoconazole, amphotericin B and terbinafin and three diazenumdiolates in concomitant uses against some fugal species. DARU J Pharml Sci. 2006, 14: 87-92.
- Saffari M, Dinehkabodi OS, Ghaffari SH, Modarressi MH, Mansouri F, Heidari M: Identification of novel p53 target genes by cDNA AFLP in glioblastoma cells. Cancer Lett. 2009, 273: 316-322. 10.1016/j.canlet.2008.08.020.View ArticlePubMed
- Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Barton R, Bijie H, Bille J, Chang SC, da Luz Martins M, Duse A: Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program. Diagn Microbiol Infect Dis. 2010, 67: 162-171. 10.1016/j.diagmicrobio.2010.01.002.View ArticlePubMed
- Bennett JE, Izumikawa K, Marr KA: Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis. Antimicrob Agents Chemother. 2004, 48: 1773-1777. 10.1128/AAC.48.5.1773-1777.2004.PubMed CentralView ArticlePubMed
- Prasad R, Gaur N, Gaur M, Komath S: Efflux pumps in drug resistance of Candida. Infect Disord Drug Targets. 2006, 6: 69-83. 10.2174/187152606784112164.View ArticlePubMed
- Vermitsky JP, Earhart KD, Smith WL, Homayouni R, Edlind TD, Rogers PD: Pdr1 regulates multidrug resistance in Candida glabrata: gene disruption and genome-wide expression studies. Mol Microbiol. 2006, 61: 704-722. 10.1111/j.1365-2958.2006.05235.x.View ArticlePubMed
- Berila N, Borecka S, Dzugasova V, Bojnansky J, Subik J: Mutations in the CgPDR1 and CgERG11 genes in azole-resistant Candida glabrata clinical isolates from Slovakia. Int J Antimicrob Agents. 2009, 33: 574-578. 10.1016/j.ijantimicag.2008.11.011.View ArticlePubMed
- Berila N, Subik J: Molecular analysis of Candida glabrata clinical isolates. Mycopathologia. 2010, 170: 99-105. 10.1007/s11046-010-9298-1.View ArticlePubMed
- Ferrari S, Ischer F, Calabrese D, Posteraro B, Sanguinetti M, Fadda G, Rohde B, Bauser C, Bader O, Sanglard D: Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence. PLoS Pathog. 2009, 5: e1000268-10.1371/journal.ppat.1000268.PubMed CentralView ArticlePubMed
- Ferrari S, Sanguinetti M, Torelli R, Posteraro B, Sanglard D: Contribution of CgPDR1-regulated genes in enhanced virulence of azole-resistant Candida glabrata. PLoS One. 2011, 6: e17589-10.1371/journal.pone.0017589.PubMed CentralView ArticlePubMed
- Karababa M, Coste AT, Rognon B, Bille J, Sanglard D: Comparison of gene expression profiles of Candida albicans azole-resistant clinical isolates and laboratory strains exposed to drugs inducing multidrug transporters. Antimicrob Agents Chemother. 2004, 48: 3064-3079. 10.1128/AAC.48.8.3064-3079.2004.PubMed CentralView ArticlePubMed
- Barski OA, Tipparaju SM, Bhatnagar A: The aldo-keto reductase superfamily and its role in drug metabolism and detoxification. Drug Metab Rev. 2008, 40: 553-624. 10.1080/03602530802431439.PubMed CentralView ArticlePubMed
- Mindnich RD, Penning TM: Aldo-keto reductase (AKR) superfamily: genomics and annotation. Hum Genomics. 2009, 3: 362-370.PubMed CentralPubMed
- Petrash JM, Murthy B, Young M, Morris K, Rikimaru L, Griest TA, Harter T: Functional genomic studies of aldo-keto reductases. Chem Biol Interact. 2001, 130: 673-683.View ArticlePubMed
- Garay-Arroyo A, Covarrubias AA: Three genes whose expression is induced by stress in Saccharomyces cerevisiae. Yeast. 1999, 15: 879-892. 10.1002/(SICI)1097-0061(199907)15:10A<879::AID-YEA428>3.0.CO;2-Q.View ArticlePubMed
- Kim ST, Huh WK, Lee BH, Kang SO: D-arabinose dehydrogenase and its gene from Saccharomyces cerevisiae. Biochim Biophys Acta. 1998, 1429: 29-39. 10.1016/S0167-4838(98)00217-9.View ArticlePubMed
- Chang Q, Griest TA, Harter TM, Mark Petrash J: Functional studies of aldo-keto reductases in Saccharomyces cerevisiae. Biochim Biophys Acta. 2007, 1773: 321-329. 10.1016/j.bbamcr.2006.10.009.PubMed CentralView ArticlePubMed
- Chang Q, Petrash JM: Disruption of aldo-keto reductase genes leads to elevated markers of oxidative stress and inositol auxotrophy in Saccharomyces cerevisiae. Biochim Biophys Acta. 2008, 1783: 237-245. 10.1016/j.bbamcr.2007.08.008.PubMed CentralView ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.